Abstract
Introduction
This analysis examines the historical and forecast performance for Merck & Co.
in the Rx pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Merck & Co.' s performance against key rivals in the prescription
pharmaceutical sector
- Assess the strategic implications of Merck & Co.' s recently announced
merger with Schering-Plough
- Analyze the impact of generic erosion across key Merck & Co. brands over
08-14 and how this threat will mitigate sales growth from new launches
| 
View Cart
